To investigate the clinical significance of the identified signature, the magnitude of EBF1, MYO6, and CARL expression levels has been correlated to the survival data of ≥ 65-year-old DLBCL patients of the training cohort. This evidence concerns the gene EBF1 and diffuse large B-cell lymphoma.